1
Leading the
new generation...
#
The first and only novel oral anticoagulant with:
6 indications approved by the FDA,
>90% of commercial and Medicare patients covered
at lowest branded co-pay,1
>8 million US prescriptions,2 and
>55,000 patients included in phase 3 trials3-11
The #1 prescribed novel oral anticoagulant in the US*12
Supported by
A comprehensive support program focused on access, education,
and adherence tools
IMPORTANT SAFETY INFORMATION
WARNING: (A) PREMATURE DISCONTINUATION OF
XARELTO® INCREASES THE RISK OF THROMBOTIC
EVENTS, (B) SPINAL/EPIDURAL HEMATOMA
A. PREMATURE DISCONTINUATION OF XARELTO®
INCREASES THE RISK OF THROMBOTIC EVENTS
Premature discontinuation of any oral anticoagulant,
including XARELTO®, increases the risk of thrombotic
events. If anticoagulation with XARELTO® is
discontinued for a reason other than pathological
bleeding or completion of a course of therapy, consider
coverage with another anticoagulant.
B. SPINAL/EPIDURAL HEMATOMA
Epidural or spinal hematomas have occurred in patients
treated with XARELTO® who are receiving neuraxial
anesthesia or undergoing spinal puncture. These
hematomas may result in long-term or permanent
paralysis. Consider these risks when scheduling patients
for spinal procedures. Factors that can increase the risk
*Among Factor Xa inhibitors and direct thrombin inhibitors.
of developing epidural or spinal hematomas in these
patients include:
Use of indwelling epidural catheters
Concomitant use of other drugs that affect
hemostasis, such as non-steroidal anti-inflammatory
drugs (NSAIDs), platelet inhibitors, other
anticoagulants,
see Drug Interactions
A history of traumatic or repeated epidural
or spinal punctures
A history of spinal deformity or spinal surgery
Optimal timing between the administration of
XARELTO® and neuraxial procedures is not known
Monitor patients frequently for signs and symptoms of
neurological impairment. If neurological compromise is
noted, urgent treatment is necessary.
Consider the benefits and risks before neuraxial
intervention in patients anticoagulated or to be
anticoagulated for thromboprophylaxis.
Please see Important Safety Information on following pages.
Please see Brief Summary of full Prescribing Information, including Boxed WARNINGS, on following pages.